High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$0
$0
Total Sells (Filtered)
$606K
$606,536
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
| KALV |
KalVista Pharmaceuticals, Inc.
|
CEO
Sell to Cover
|
2026-03-09 | $107,633 | S | Form 4 |
|
KALV
S
KalVista Pharmaceuticals, Inc.
Audhya Paul K.
• Officer • CHIEF MEDICAL OFFICER
Sell to Cover
2026-02-23
$83,345
|
||||||
| KALV |
KalVista Pharmaceuticals, Inc.
|
Officer • CHIEF MEDICAL OFFICER
Sell to Cover
|
2026-02-23 | $83,345 | S | Form 4 |
| KALV |
KalVista Pharmaceuticals, Inc.
|
CEO
Sell to Cover
|
2026-02-23 | $156,197 | S | Form 4 |
|
KALV
S
KalVista Pharmaceuticals, Inc.
Piekos Brian
• CFO
Sell to CoverΔOwn -11.4%
2026-02-23
$27,507
|
||||||
| KALV |
KalVista Pharmaceuticals, Inc.
|
CFO
Sell to CoverΔOwn -11.4%
|
2026-02-23 | $27,507 | S | Form 4 |
|
KALV
S
KalVista Pharmaceuticals, Inc.
Sweeny Nicole
• Officer • Chief Commercial Officer
Sell to Cover
2026-02-23
$61,878
|
||||||
| KALV |
KalVista Pharmaceuticals, Inc.
|
Officer • Chief Commercial Officer
Sell to Cover
|
2026-02-23 | $61,878 | S | Form 4 |
|
KALV
S
KalVista Pharmaceuticals, Inc.
Yea Christopher
• Officer • CHIEF DEVELOPMENT OFFICER
Sell to Cover
2026-02-23
$67,669
|
||||||
| KALV |
KalVista Pharmaceuticals, Inc.
|
Officer • CHIEF DEVELOPMENT OFFICER
Sell to Cover
|
2026-02-23 | $67,669 | S | Form 4 |
|
KALV
S
KalVista Pharmaceuticals, Inc.
Audhya Paul K.
• Officer • CHIEF MEDICAL OFFICER
Sell to Cover
2026-02-18
$17,445
|
||||||
| KALV |
KalVista Pharmaceuticals, Inc.
|
Officer • CHIEF MEDICAL OFFICER
Sell to Cover
|
2026-02-18 | $17,445 | S | Form 4 |
| KALV |
KalVista Pharmaceuticals, Inc.
|
CEO
Sell to Cover
|
2026-02-18 | $15,570 | S | Form 4 |
|
KALV
S
KalVista Pharmaceuticals, Inc.
Yea Christopher
• Officer • CHIEF DEVELOPMENT OFFICER
Sell to Cover
2026-02-18
$16,635
|
||||||
| KALV |
KalVista Pharmaceuticals, Inc.
|
Officer • CHIEF DEVELOPMENT OFFICER
Sell to Cover
|
2026-02-18 | $16,635 | S | Form 4 |
| KALV |
KalVista Pharmaceuticals, Inc.
|
CEO
Sell to Cover
|
2026-02-12 | $52,658 | S | Form 4 |